As populations age globally, the deterioration of immune function — termed immunosenescence — stands as one of the most consequential yet least therapeutically addressed hallmarks of aging. A framework that combines cutting-edge bioengineering with immunology could fundamentally change how researchers study and eventually reverse this decline, with direct implications for vaccine efficacy in older adults, chronic inflammation management, and susceptibility to infectious disease.
Published in Nature Aging, this review by Nikolich and colleagues synthesizes an emerging field termed immunoengineering, cataloguing tools designed to probe and manipulate the aging immune landscape. The authors highlight three converging technological fronts: advances in extracellular matrix (ECM) scaffolds and biomaterials that can replicate the aged tissue microenvironment in vitro; microphysiological systems and organoids that model thymic involution, lymph node dysfunction, and inflammaging with greater biological fidelity than traditional cell culture; and tissue-targeted delivery platforms for vaccines and immunomodulatory drugs designed to overcome the blunted responses seen in aged immune architectures. Together these represent a methodological leap beyond standard mouse-model immunology toward human-relevant, age-contextualized research.
The significance here is largely translational and methodological rather than immediately clinical. Immunosenescence research has long been hampered by the inadequacy of standard laboratory models — young inbred mice bear little resemblance to the heterogeneous immune landscapes of 70-year-old humans. By building aged tissue analogs using biomaterials that mimic ECM stiffness and composition changes that occur with aging, researchers can now test interventions in environments that more accurately reflect human biology. The organoid and microphysiological angles are particularly promising: age-accurate thymus organoids could accelerate screening of thymic rejuvenation compounds. Key limitations remain — most described platforms are pre-clinical or proof-of-concept, and translating engineered model findings to human therapeutic outcomes requires extensive validation. This review reads as a timely field-organizing contribution that may accelerate the pace of genuinely translatable immunosenescence research.
